Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1CNS 1

Conditions

Melanoma 82Carcinoma, Non-Small-Cell Lung 72Carcinoma, Renal Cell 42Neoplasm Metastasis 31Neoplasms 29Squamous Cell Carcinoma of Head and Neck 26Lung Neoplasms 25Colorectal Neoplasms 23Carcinoma, Hepatocellular 20Hodgkin Disease 18Small Cell Lung Carcinoma 17Prostatic Neoplasms 14Carcinoma, Transitional Cell 13Head and Neck Neoplasms 12Urinary Bladder Neoplasms 11Pancreatic Neoplasms 11Ovarian Neoplasms 11Multiple Myeloma 11Advanced Cancer 11Triple Negative Breast Neoplasms 10Lymphoma 10Glioblastoma 10Kidney Neoplasms 9Breast Neoplasms 9Recurrence 8Lymphoma, Non-Hodgkin 8Leukemia, Myeloid, Acute 8Glioma 8Stomach Neoplasms 7Myelodysplastic Syndromes 7

Interventions

Ifosfamide 6X-Rays 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Filgrastim 5Etoposide 5Doxorubicin 5Cyclophosphamide 5Vincristine 4Temozolomide 4Specimen Handling 4Radiotherapy 4Nuclear Medicine Department, Hospital 4Melphalan 4Thiotepa 3Irinotecan 3Biopsy 3Bevacizumab 3ulixertinib 2trioctyl phosphine oxide 2tipifarnib 2temsirolimus 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2cixutumumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neuroectodermal Tumors, Primitive, Peripheral × Nivolumab × Clear all
NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

National Cancer Institute (NCI)

Phase 1/2 Completed
140 enrolled 23 charts
CNSDermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡